Enterprise Value
192.8B
Cash
10.51B
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.14%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Polivy (CD79b) w/ R-CHP Details Cancer, Diffuse large B cell lymphoma | Approved Quarterly sales | |
Evrysdi (risdiplam) Details Spinal muscular atrophy , Rare diseases | Approved Quarterly sales | |
Mosunetuzumab (Lunsumio) Details Cancer, Blood cancer, Follicular lymphoma | Approved Quarterly sales | |
Vabysmo® (faricimab) Details Retinal vein occlusion | Approved Quarterly sales | |
Alecensa® (alectinib) Details Non-small cell lung carcinoma | Approved Quarterly sales | |
Columvi® (glofitamab-gxbm) Details Diffuse large B cell lymphoma, Cancer | Approved Quarterly sales | |
Xolair® (omalizumab) Details Allergic Reactions (type I), Allergy | Approved Quarterly sales | |
Tecentriq w/ ENHANZE® Details Solid tumor/s, Cancer | PDUFA Approval decision | |
Inavolisib + palbociclib & fulvestrant Details Cancer, Breast cancer, ER+/HER2- breast cancer | PDUFA Approval decision | |
OCREVUS (ocrelizumab) w/ ENHANZE Details Multiple sclerosis | PDUFA Approval decision | |
Susvimo Details Diabetic macular edema, Diabetic retinopathy | BLA Acceptance for review | |
Fenebrutinib Details Multiple sclerosis, Autoimmune disease | Phase 3 Data readout | |
Tecentriq SC (subcutaneous) Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Tecentriq® (atezolizumab) +Chemo Details Cancer, Solid tumor/s, Triple-negative breast cancer | Phase 3 Data readout | |
Hemlibra® (emicizumab) Details Hemophilia | Phase 3 Update | |
Lunsumio + Polivy Details Cancer, Blood cancer, Diffuse large B cell lymphoma | Phase 3 Update | |
Tecentriq® (atezolizumab) +Avastin® Details Cancer, Solid tumor/s, Hepatocellular carcinoma | Phase 3 Update | |
Crovalimab Details Paroxysmal nocturnal hemoglobinuria | Phase 3 Update | |
Gantenerumab Details Alzheimer's disease | Phase 3 Update | |
Columvi® + GemOx Details Cancer, Diffuse large B cell lymphoma, Blood cancer | Phase 3 Update | |
Mosunetuzumab (Lunsumio) Details Cancer, Follicular lymphoma, Blood cancer | Phase 1 Data readout | |
Phase 1 Data readout | ||
Phase 1 Update | ||
Anti-IL-6 monoclonal antibody Details Eye disease , Macular edema | Phase 1 Update | |
CT-996 (oral GLP-1 receptor agonist) Details Obesity, Diabetes mellitus , Type 2 diabetes | Phase 1 Update | |
Tecentriq+/- Tiragolumab Details Cancer, Non-small cell lung carcinoma | Failed Discontinued |